BridgeBio Pharma, Inc. — Director's Dealing 2022

Jan 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2022-01-04

Reporting Person: Dachille Douglas A. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-04	Common Stock	P	5000	$16.82	Acquired	5000	Indirect
2022-01-05	Common Stock	P	5000	$15.91	Acquired	10000	Indirect

Footnotes

F1: These shares are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person's children, for which the reporting person's spouse is the trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.